Dorzagliatin is a new, dual-acting, allosteric glucokinase activator that targets both pancreatic and hepatic glucokinases.
In a related editorial, the author questions whether these promising data could be extrapolated to other non-Chinese patients remains unknown. “The findings of this proof-of-concept study require confirmation in phase 3 trials in larger populations over a longer study period. Even if glucokinase activators such as dorzagliatin succeed in being commercialised, their positioning among the armamentarium of medications already available for the treatment of type 2 diabetes will depend on comparative efficacy and safety profiles, ease of use (especially with twice daily administration), and cost.